Canadian contract manufacturer PharmEng International has managed to trim down its costs once again, but is still feeling the pain associated with the opening of its new facility in Sydney, Nova Scotia, and posted a loss of over C$8m (€5m).
Icelandic generics firm Actavis plans to use Malta as a distribution hub for the supply of drugs to the emerging African pharmaceutical market, according to reports in the Maltese press.
Qatar and Egypt are to set up a new drug manufacturing plant at a facility in Qatar, according to BusinessIntelligence. The new facility will begin by producing soluble drugs for the emerging Qatari and Egyptian drug markets.
Postponement of this year’s CPhI and P-MEC India events for “security reasons” may be only the first impact of last week’s Mumbai terror attacks on the country’s outsourcing industry, according to PwC’s life sciences head Sujay Shetty.
European facilities owned by Israel’s Teva Pharmaceuticals and French drugmaker Servier are among the firms raided by the EC’s competition unit earlier this week, according to media reports.
The US Food and Drug Administration has opened offices in three Chinese cities – Beijing, Shanghai and Guangzhou – to help improve the safety of medicines and ingredients imported into the US.
Taiwanese API maker ScinoPharm has been granted a US patent for new crystalline forms of irinotecan which are designed to allow for easier filtration during production processing.
A member of the US Congress has called on the GAO to launch an investigation into the FDA’s handling of the heparin crisis, citing “unanswered questions concerning [the] deaths”.
Chinese CRO Tigermed Consulting has teamed up with Russian and South Korean counterparts OCT and LSK to establish a global clinical trials network and expand its geographic footprint.
AstraZeneca is to cut 1,400 jobs and close more manufacturing facilities by 2013, as it attempts to slim down in preparation for impending generic competition for some of its cornerstone drugs.
DPT Laboratories chose this year’s AAPS in Atlanta to showcase its research and development capability with a unique poster presentation examining the role of various excipients in nasal drug delivery applications.
Demand for glycerin as an ingredient in pharmaceuticals, personal care and other products is expected to show brisk growth out 2015, when demand around the world is expected to reach 3.39 billion pounds, according to market research firm Global Industry...
Barrack Obama’s election as US president has been roundly welcomed by India’s generics sector, despite his somewhat contradictory desire to reduce the level of outsourcing but not "shy away" from globalisation.
Taiwan’s efforts to position itself as a major biotechnology hub received a further boost today with the opening of Merck KGaA’s dedicated technology training centre in Xizhi City, Taipei County.
The NAFDAC has banned 22 firms that it says are involved in the manufacture of fake drugs from ever again selling pharmaceuticals in Nigeria, as part of a countrywide clampdown.
The pharmaceutical industry must adapt its processes and strategies to cope with a new, tougher operating environment, according to Stefan Borgas, CEO of Lonza.
Wyeth Medica, an Irish subsidiary of US drugmaker Wyeth, plans to cut 250 jobs at its manufacturing plant in Newbridge, County Kildare, according to media reports.
The International Pharmaceutical Excipients Council (IPEC) of Europe has outlined the actions it is taking as it continues to develop awareness of the need for safe excipients.
Canada’s Ethica Clinical Research has expanded into the emerging Latin American market via a joint venture with Argentinean contract research organisation Blanchard y Asociados.
Exclusive interview with IPEC China chairman Nevin Cheng
IPEC China must become a “harmonisation bridge between China and other countries,” according to Colorcon’s Nevin Cheng who was recently elected chairman of the new organisation.
Bilcare GCS, the clinical supplies arm of Indian packaging giant Bilcare, has considerably expanded its Phase III trial offering in an effort to provide drugmakers with a complete package.
Pharmaceutical companies in the developed world have already
shifted substantial manufacturing and clinical trial work to
emerging economies such as China and India, but a new study suggest
they are increasingly counting on these...
The contract manufacturing sector is likely to enjoy "continued
and accelerating growth" in the coming years as big pharma
companies continue to increase the level of outsourcing, with firms
now viewing outsourcing as the...
A US senator has asked the Food and Drug Administration (FDA) for a
probe into outsourcing of production for pharmaceuticals, as well
as ways to make drugmakers accountable for products which fail to
meet quality standards.
Although there has been considerable industry effort to monitor and
control the distribution of pharmaceutical raw materials, the
voluntary nature of this regulation means that the supply network
is still susceptible to unscrupulous...
Pharmaceutical companies are having to radically change their
practices when it comes to tackling emerging markets such as China,
India, Russia and Brazil, according to IMS.
China is on course to having its own version of the International
Pharmaceutical Excipients Council - joining its fellow
organisations in Europe, the Americas and Japan.
The healthcare logistics industry is currently experiencing a shift
toward globalisation, supply chain simplification and delivery
specialisation, says an industry expert.
Draft legislation has been put forward which would require the US
Food and Drug Administration (FDA) to inspect foreign manufacturing
plants every four years.
The US Food and Drug Administration (FDA) has revealed it will be
operating on the ground in China imminently, while the Drug
Information Association (DIA) has just planted itself in Asia's
other pharma don, India.
The US Food and Drug Administration (FDA) believes that the
contamination of Baxter's blood thinner heparin, which has been
linked to 62 deaths in the US, may have been due to the deliberate
replacement of some ingredients with...
At present India appears to be beating China in the race for Asia's
top clinical spot, according to new figures published by india´s
Planning Commission.
Despite all the hype over clinical trial offshoring, the US still
dwarfs the scene, with emerging countries as yet only a blip on the
radar, a unique new study reveals.
The pharmacopoeias of the US and China will work more closely
together in future in a bid to improve the quality of medicines
available in both countries.
The continuing clinical trials globalisation trend will cause the
complexity of running these studies to dramatically increase by
2010, according to a new report.
Pharmaceutical manufacturers, distributors and retailers alike have
welcomed a unanimous vote by the California State Board of Pharmacy
to delay for another two years the implementation of electronic
pedigree requirements for tracking...
The globalisation of the supply chain increasingly challenges the
US Food and Drug Administration's ability to ensure the quality of
pharmaceuticals on the US market, acknowledges the acting director
of the agency's Center...
Novartis has lent impetus to the growing trend towards
philanthropic R&D in the pharmaceutical industry by opening a
new research institute in Siena, Italy "with a non-profit
mission to exclusively focus on the development...
Chinese outsourcing firm Radiant Pharma & Tech is blasting
through the stereotypes being pinned on companies operating in
low-cost economies, with the relatively young firm hoping to give
companies in established markets a run...
Members of the Synthetic Organic Chemical Manufacturers Association
(SOCMA) have slammed competitors from emerging markets, claiming
poor quality goods and lack of technological competence in regions
such as China, India and Eastern...
Outsourcing will be seen as being "instrumental" in the
eyes of healthcare and biopharma firms this year as the focus on
cost reduction continues to increase, according to a new report.
Product recalls in the UK due to health and safety concerns have
shot up to their highest level, with the rise in outsourcing to
China finger pointed for much of the blame.
As of next year Chinese pharmaceutical manufacturers will face a
tougher time gaining good manufacturing practice (GMP)
certification after the country's regulator signalled new and
stricter standards were on the way.
This week two sets of contract research organisations (CROs) have
announced plans to link arms in order to spread their reach further
into this increasingly globalised marketplace.
